# clm_F56438C2065F

subject: Regeneron Pharmaceuticals (/record/regeneron-pharmaceuticals.md)  
predicate: quarterly_research_and_development  
value: 138,862,000 United States dollar  
valid_from: 2012-03-31  
valid_to: 2012-06-30  
published: 2012-04-26  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_1557BB809F3B  
last_updated: 2026-11-08  
cite: AsOf. "Regeneron Pharmaceuticals quarterly research and development: 138,862,000 United States dollar", as of 2012-03-31 (until 2012-06-30). Claim clm_F56438C2065F, https://asof.is/claim/clm_F56438C2065F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2012, filed 2012-04-26  

## Sources

- https://www.sec.gov/Archives/edgar/data/872589/000120677412001689/0001206774-12-001689-index.htm (primary, SEC EDGAR 10-Q Q1 FY2012, published 2012-04-26)

## Supersedes

- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_research_and_development | 127,924,000 United States dollar | valid 2011-09-30 to 2012-03-31 | conf 0.95 | superseded | superseded_by [clm_F56438C2065F](/claim/clm_F56438C2065F.md) | [clm_D248A8950FA4](/claim/clm_D248A8950FA4.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.